Patents by Inventor Frederick GOLDBERG

Frederick GOLDBERG has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • 2,6,9-trisubstituted purines
    Patent number: 12441744
    Abstract: Compounds having the structure of Formula (I): and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, and R5 are as defined in the specification; pharmaceutical compositions comprising such compounds and salts; use of such compounds and salts to treat or prevent cyclin-dependent kinase 2 (CDK2)-mediated conditions; kits comprising such compounds and salts; and methods for manufacturing such compounds and salts.
    Type: Grant
    Filed: January 27, 2025
    Date of Patent: October 14, 2025
    Inventors: Bernard Barlaam, Michael Bodnarchuk, Avipsa Ghosh, Frederick Goldberg, Sudhir Hande, Phillip Lichtor, Kun Song, Qibin Su, Reem Telmesani, James Sheppeck
  • 2,6,9-TRISUBSTITUTED PURINES
    Publication number: 20250197425
    Abstract: Compounds having the structure of Formula (I): and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, and R5 are as defined in the specification; pharmaceutical compositions comprising such compounds and salts; use of such compounds and salts to treat or prevent cyclin-dependent kinase 2 (CDK2)-mediated conditions; kits comprising such compounds and salts; and methods for manufacturing such compounds and salts.
    Type: Application
    Filed: January 27, 2025
    Publication date: June 19, 2025
    Inventors: Bernard BARLAAM, Michael BODNARCHUK, Avipsa GHOSH, Frederick GOLDBERG, Sudhir HANDE, Phillip LICHTOR, Kun SONG, Qibin SU, Reem TELMESANI, James SHEPPECK
  • ER DEGRADERS AND USES THEREOF
    Publication number: 20250177539
    Abstract: This specification relates to compounds according to Formula (I), which are of degraders of ER, to pharmaceutical compositions containing them, and to their use in therapy for the treatment of ER-sensitive and/or ER-directed diseases and disorders.
    Type: Application
    Filed: November 26, 2024
    Publication date: June 5, 2025
    Inventors: Niall ANDERSON, Marc André DÄMGEN, Laura EVANS, Charlene FALLAN, Frederick GOLDBERG, Thomas George Christopher HAYHOW, Johannes Wilhelmus Maria NISSINK, Martin John PACKER, James SCOTT, Oliver STEWARD
  • 2,6,9-TRISUBSTITUTED PURINES
    Publication number: 20240247001
    Abstract: Compounds having the structure of Formula (I): and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, and R5 are as defined in the specification; pharmaceutical compositions comprising such compounds and salts; use of such compounds and salts to treat or prevent cyclin-dependent kinase 2 (CDK2)-mediated conditions; kits comprising such compounds and salts; and methods for manufacturing such compounds and salts.
    Type: Application
    Filed: December 15, 2023
    Publication date: July 25, 2024
    Inventors: Bernard BARLAAM, Michael BODNARCHUK, Avipsa GHOSH, Frederick GOLDBERG, Sudhir HANDE, Phillip LICHTOR, Kun SONG, Qibin SU, Reem TELMESANI, James SHEPPECK